High burden of metabolic comorbidities in a citywide cohort of HIV outpatients: evolving health care needs of people aging with HIV in Washington, DC

HIV Medicine

Volumn 18, Issue 10, 2017, Pages 724-735

  Levy, M E ^a   Greenberg, A E ^a   Hart, R ^b   Powers Happ, L ^a   Hadigan, C ^c   Castel, A ^a   Benator, Debra ^d   Kumar, Princy ^d   Goldstein, Deborah ^d   Hardy, David ^d   Parenti, David ^d   Ruiz, Maria Elena ^d   D'Angelo, Lawrence ^d   Rakhmanina, Natella ^d   Rana, Sohail ^d   Doshi, Saumil ^d   Hebou, Annick ^d   Fernandez, Ricardo ^d   Abbott, Stephen ^d   Kharfen, Michael ^d   Masur, Henry ^d   more..

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b CERNER CORPORATION   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NONE

Author keywords

diabetes; dyslipidaemia; HIV; hypertension; metabolic comorbidities; obesity

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; AGED; AGING; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISTRICT OF COLUMBIA; DYSLIPIDEMIA; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE NEED; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ICD-9; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; OUTPATIENT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISTRICT OF COLUMBIA; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; OUTPATIENTS; PREVALENCE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85019241505     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12516     Document Type: Article

References (53)

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382: 1525–1533.
2. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012; 13: 453–468.
3. Feinstein MJ, Bahiru E, Achenbach C et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol 2016; 117: 214–220.
4. Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis 2013; 13: 964–975.
5. Lazarus J, Nielsen K. HIV and people over 50 years old in Europe. HIV Med 2010; 11: 479–481.
6. Shahmanesh M, Schultze A, Burns F et al. The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS 2016; 30: 2505–2518.
7. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179–1193.
8. Friis-Moller N, Ryom L, Smith C et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-hiv drugs (D:A:D) study. Eur J Prev Cardiol 2016; 23: 214–223.
9. Glass T, Ungsedhapand C, Wolbers M et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7: 404–410.
10. Hasse B, Tarr PE, Marques-Vidal P et al. Strong impact of smoking on multimorbidity and cardiovascular risk among human immunodeficiency virus-infected individuals in comparison with the general population. Open Forum Infect Dis 2015; 8: ofv108.
11. Buchacz K, Baker RK, Palella FJ Jr et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther 2013; 18: 65–75.
12. Sico JJ, Chang C-CH, So-Armah K et al. HIV status and the risk of ischemic stroke among men. Neurology 2015; 84: 1933–1940.
13. Armah KA, McGinnis K, Baker J et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55: 126–136.
14. Monroe AK, Fu W, Zikusoka MN et al. Low-density lipoprotein cholesterol levels and statin treatment by HIV status among Multicenter AIDS Cohort Study men. AIDS Res Hum Retroviruses 2015; 31: 593–602.
15. Kaplan RC, Kingsley LA, Sharrett AR et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45: 1074–1081.
16. Abraham AG, Darilay A, McKay H et al. Kidney dysfunction and markers of inflammation in the multicenter AIDS cohort study. J Infect Dis 2015; 212: 1100–1110.
17. Sobieszczyk ME, Hoover DR, Anastos K et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008; 48: 272–280.
18. Schwartz JB, Moore KL, Yin M et al. Relationship of vitamin D, HIV, HIV treatment, and lipid levels in the Women's Interagency HIV Study of HIV-infected and uninfected women in the United States. J Int Assoc Provid AIDS Care 2014; 13: 250–259.
19. Koethe JR, Jenkins CA, Lau B et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses 2016; 32: 50–58.
20. Koethe J, Jenkins C, Lau B et al. Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998–2010. HIV Med 2015; 16: 572–577.
21. Myerson M, Poltavskiy E, Armstrong EJ, Kim S, Sharp V, Bang H. Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 HIV outpatients. J Acquir Immune Defic Syndr 2014; 66: 370–377.
22. Srinivasa S, Grinspoon SK. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol 2014; 170: R185–R202.
23. Greenberg AE, Hays H, Castel AD et al. Development of a large urban longitudinal HIV clinical cohort using a web-based platform to merge electronically and manually abstracted data from disparate medical record systems: technical challenges and innovative solutions. J Am Med Inform Assoc 2016; 23: 635–643.
24. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D Study. AIDS 2010; 24: 1537–1548.
25. Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health 2010; 100: 1896–1903.
26. Crothers K, Goulet JL, Rodriguez-Barradas MC et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev 2009; 21: 40–53.
27. Guaraldi G, Orlando G, Zona S et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120–1126.
28. Goulet JL, Fultz SL, Rimland D et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45: 1593–1601.
29. Rodriguez-Penney AT, Iudicello JE, Riggs PK et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS 2013; 27: 5–16.
30. Freiberg MS, Leaf DA, Goulet JL et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med 2009; 24: 334–340.
31. Estrada V, Bernardino JI, Masia M et al. Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. HIV Clin Trials 2015; 16: 57–65.
32. Reinsch N, Neuhaus K, Esser S et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol 2012; 19: 267–274.
33. Lichtenstein KA, Armon C, Buchacz K et al. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis 2013; 10: E10.
34. Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med 2013; 126: S38–S48.
35. Khatib R, Schwalm J-D, Yusuf S et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One 2014; 9: e84238.
36. Chee YJ, Chan HHV, Tan NC. Understanding patients’ perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review Singapore Med J 2014; 55: 416–421.
37. Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 2013; 30: 613–628.
38. Fitch KV, Anderson EJ, Hubbard JL et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 2006; 20: 1843–1850.
39. Fleetwood C, Campa A, Martinez S et al. Nutritional intervention decreases risk of metabolic syndrome and improves quality of diet. FASEB J 2015; 29: 906–910.
40. Moscou-Jackson G, Commodore-Mensah Y, Farley J, DiGiacomo M. Smoking-cessation interventions in people living with HIV infection: a systematic review. J Assoc Nurses AIDS Care 2014; 25: 32–45.
41. Havlik RJ, Brennan M, Karpiak SE. Comorbidities and depression in older adults with HIV. Sex Health 2011; 8: 551–559.
42. Freiberg MS, McGinnis KA, Kraemer K et al. The association between alcohol consumption and prevalent cardiovascular diseases among HIV infected and uninfected men. J Acquir Immune Defic Syndr 2010; 53: 247–253.
43. Butt AA, McGinnis K, Rodriguez-Barradas MC et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23: 1227–1234.
44. Capeau J, Bouteloup V, Katlama C et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012; 26: 303–314.
45. Seaberg EC, Munoz A, Lu M et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19: 953–960.
46. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20: 1019–1026.
47. Dube MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab 2011; 25: 429–442.
48. Oliviero U, Bonadies G, Apuzzi V et al. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 2009; 204: 586–589.
49. Bonfanti P, De Socio GL, Marconi P et al. Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res 2010; 8: 165–171.
50. Paula AA, Falcao MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther 2013; 10: 32.
51. Manner IW, Troseid M, Oektedalen O, Baekken M, Os I. Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals. J Clin Hypertens (Greenwich) 2013; 15: 101–106.
52. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7: 69–76.
53. Chu C, Selwyn PA. An epidemic in evolution: the need for new models of HIV care in the chronic disease era. J Urban Health 2011; 88: 556–566.